These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 31097097)

  • 1. Association between antibiotic-immunotherapy exposure ratio and outcome in metastatic non small cell lung cancer.
    Galli G; Triulzi T; Proto C; Signorelli D; Imbimbo M; Poggi M; Fucà G; Ganzinelli M; Vitali M; Palmieri D; Tessari A; de Braud F; Garassino MC; Colombo MP; Lo Russo G
    Lung Cancer; 2019 Jun; 132():72-78. PubMed ID: 31097097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of immunotherapy in elderly patients with non-small cell lung cancer.
    Galli G; De Toma A; Pagani F; Randon G; Trevisan B; Prelaj A; Ferrara R; Proto C; Signorelli D; Ganzinelli M; Zilembo N; de Braud F; Garassino MC; Lo Russo G
    Lung Cancer; 2019 Nov; 137():38-42. PubMed ID: 31526910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials.
    Maymani H; Hess K; Groisberg R; Hong DS; Naing A; Piha-Paul S; Janku F; Fu S; Tsimberidou AM; Pant S; Karp D; Liu S; Sun M; Heymach J; Simon G; Meric-Bernstam F; Subbiah V
    Lung Cancer; 2018 Jun; 120():137-141. PubMed ID: 29748008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibiotic Usage Reduced Overall Survival by over 70% in Non-small Cell Lung Cancer Patients on Anti-PD-1 Immunotherapy.
    Hamada K; Yoshimura K; Hirasawa Y; Hosonuma M; Murayama M; Narikawa Y; Ariizumi H; Ohkuma R; Shida M; Kubota Y; Matsukuma S; Ishiguro T; Sambe T; Horiike A; Kuramasu A; Wada S; Tsurutani J; Inoue E; Uchida N; Kiuchi Y; Kobayashi S; Hoffman RM; Tsunoda T
    Anticancer Res; 2021 Oct; 41(10):4985-4993. PubMed ID: 34593446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic implication of erector spinae muscles in non-small-cell lung cancer patients treated with immuno-oncology combinatorial chemotherapy.
    Araki T; Kitaguchi Y; Suzuki Y; Komatsu M; Sonehara K; Wada Y; Tateishi K; Hanaoka M
    Thorac Cancer; 2021 Nov; 12(21):2857-2864. PubMed ID: 34599854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.
    Diem S; Schmid S; Krapf M; Flatz L; Born D; Jochum W; Templeton AJ; Früh M
    Lung Cancer; 2017 Sep; 111():176-181. PubMed ID: 28838390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NSCLC Immunotherapy Efficacy and Antibiotic Use: A Systematic Review and Meta-Analysis.
    Lurienne L; Cervesi J; Duhalde L; de Gunzburg J; Andremont A; Zalcman G; Buffet R; Bandinelli PA
    J Thorac Oncol; 2020 Jul; 15(7):1147-1159. PubMed ID: 32173463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Body Composition in Advanced Non-Small Cell Lung Cancer Treated With Immunotherapy.
    Chaunzwa TL; Qian JM; Li Q; Ricciuti B; Nuernberg L; Johnson JW; Weiss J; Zhang Z; MacKay J; Kagiampakis I; Bikiel D; Di Federico A; Alessi JV; Mak RH; Jacob E; Awad MM; Aerts HJWL
    JAMA Oncol; 2024 Jun; 10(6):773-783. PubMed ID: 38780929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rare targetable drivers (RTDs) in non-small cell lung cancer (NSCLC): Outcomes with immune check-point inhibitors (ICPi).
    Dudnik E; Bshara E; Grubstein A; Fridel L; Shochat T; Roisman LC; Ilouze M; Rozenblum AB; Geva S; Zer A; Rotem O; Allen AM; Peled N
    Lung Cancer; 2018 Oct; 124():117-124. PubMed ID: 30268448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibiotics are associated with attenuated efficacy of anti-PD-1/PD-L1 therapies in Chinese patients with advanced non-small cell lung cancer.
    Zhao S; Gao G; Li W; Li X; Zhao C; Jiang T; Jia Y; He Y; Li A; Su C; Ren S; Chen X; Zhou C
    Lung Cancer; 2019 Apr; 130():10-17. PubMed ID: 30885328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative analysis of antibiotic exposure association with clinical outcomes of chemotherapy versus immunotherapy across three tumour types.
    Kulkarni AA; Ebadi M; Zhang S; Meybodi MA; Ali AM; DeFor T; Shanley R; Weisdorf D; Ryan C; Vasu S; Rashidi A; Patel MR
    ESMO Open; 2020 Sep; 5(5):e000803. PubMed ID: 32900789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low Baseline Serum Sodium Concentration Is Associated with Poor Clinical Outcomes in Metastatic Non-Small Cell Lung Cancer Patients Treated with Immunotherapy.
    Fucà G; Galli G; Poggi M; Lo Russo G; Proto C; Imbimbo M; Vitali M; Ganzinelli M; Lanti C; Molino G; Stangoni F; Zilembo N; de Braud F; Garassino MC; Signorelli D
    Target Oncol; 2018 Dec; 13(6):795-800. PubMed ID: 30306460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of prior fluoroquinolone treatment with survival outcomes of immune checkpoint inhibitors in Asia.
    Lu PH; Tsai TC; Chang JW; Deng ST; Cheng CY
    J Clin Pharm Ther; 2021 Apr; 46(2):408-414. PubMed ID: 33332621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients.
    Cortellini A; Chiari R; Ricciuti B; Metro G; Perrone F; Tiseo M; Bersanelli M; Bordi P; Santini D; Giusti R; Grassadonia A; Di Marino P; Tinari N; De Tursi M; Zoratto F; Veltri E; Malorgio F; Garufi C; Russano M; Anesi C; Zeppola T; Filetti M; Marchetti P; Berardi R; Rinaldi S; Tudini M; Silva RR; Pireddu A; Atzori F; Iacono D; Migliorino MR; Porzio G; Cannita K; Ficorella C; Buti S
    Clin Lung Cancer; 2019 Jul; 20(4):237-247.e1. PubMed ID: 30885550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating Fatty Acid Profile as a Biomarker for Immunotherapy in Advanced Non-Small Cell Lung Cancer.
    Galli G; Corsetto PA; Proto C; Lo Russo G; Ganzinelli M; Rulli E; Legramandi L; Morelli D; Ferrara R; Prelaj A; Signorelli D; De Toma A; Brambilla M; Occhipinti M; Manglaviti S; Boeri M; Martinetti A; Vingiani A; Colombo MP; Rizzo AM; Torri V; de Braud F; Sangaletti S; Sica A; Garassino MC
    Clin Lung Cancer; 2022 Nov; 23(7):e489-e499. PubMed ID: 35948460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibiotic Use Does Not Appear to Influence Response to Nivolumab.
    Kaderbhai C; Richard C; Fumet JD; Aarnink A; Foucher P; Coudert B; Favier L; Lagrange A; Limagne E; Boidot R; Ghiringhelli F
    Anticancer Res; 2017 Jun; 37(6):3195-3200. PubMed ID: 28551664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of baseline symptom burden with efficacy outcomes: Exploratory analysis from the randomized phase III REVEL study in advanced non-small-cell lung cancer.
    Pérol M; Winfree KB; Cuyun Carter G; Lin Cui Z; Bowman L; Garon EB
    Lung Cancer; 2019 May; 131():6-13. PubMed ID: 31027699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer.
    Grangeon M; Tomasini P; Chaleat S; Jeanson A; Souquet-Bressand M; Khobta N; Bermudez J; Trigui Y; Greillier L; Blanchon M; Boucekine M; Mascaux C; Barlesi F
    Clin Lung Cancer; 2019 May; 20(3):201-207. PubMed ID: 30442524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overall survival according to immunotherapy and radiation treatment for metastatic non-small-cell lung cancer: a National Cancer Database analysis.
    Foster CC; Sher DJ; Rusthoven CG; Verma V; Spiotto MT; Weichselbaum RR; Koshy M
    Radiat Oncol; 2019 Jan; 14(1):18. PubMed ID: 30691492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progression-free survival and one-year milestone survival as surrogates for overall survival in previously treated advanced non-small cell lung cancer.
    Zhao S; Zhang Z; Zhang Y; Hong S; Zhou T; Yang Y; Fang W; Zhao H; Zhang L
    Int J Cancer; 2019 Jun; 144(11):2854-2866. PubMed ID: 30430561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.